Vanguard Group Inc. Buys 437,462 Shares of Phreesia, Inc. $PHR

Vanguard Group Inc. boosted its stake in shares of Phreesia, Inc. (NYSE:PHR) by 8.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,704,786 shares of the company’s stock after buying an additional 437,462 shares during the quarter. Vanguard Group Inc. owned approximately 9.52% of Phreesia worth $134,177,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in PHR. PNC Financial Services Group Inc. raised its stake in shares of Phreesia by 30.3% during the third quarter. PNC Financial Services Group Inc. now owns 26,045 shares of the company’s stock valued at $613,000 after acquiring an additional 6,062 shares in the last quarter. Essex Investment Management Co. LLC lifted its holdings in shares of Phreesia by 3.6% in the 3rd quarter. Essex Investment Management Co. LLC now owns 104,906 shares of the company’s stock worth $2,467,000 after buying an additional 3,676 shares during the period. Versor Investments LP bought a new position in shares of Phreesia during the 3rd quarter worth $247,000. Wesbanco Bank Inc. grew its position in shares of Phreesia by 40.2% during the 3rd quarter. Wesbanco Bank Inc. now owns 64,500 shares of the company’s stock worth $1,517,000 after buying an additional 18,500 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in shares of Phreesia by 129.0% during the third quarter. Smartleaf Asset Management LLC now owns 6,449 shares of the company’s stock valued at $152,000 after buying an additional 3,633 shares during the period. 92.10% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. BMO Capital Markets initiated coverage on shares of Phreesia in a report on Thursday, November 13th. They set an “outperform” rating and a $32.00 target price on the stock. Mizuho set a $22.00 price objective on shares of Phreesia in a report on Wednesday, February 4th. Wells Fargo & Company started coverage on Phreesia in a report on Thursday, January 8th. They set an “overweight” rating and a $30.00 target price for the company. Wall Street Zen cut Phreesia from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 8th. Finally, Robert W. Baird reduced their price target on Phreesia from $31.00 to $25.00 and set an “outperform” rating for the company in a research report on Wednesday, December 10th. Seventeen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Phreesia presently has a consensus rating of “Moderate Buy” and an average target price of $29.12.

Insider Buying and Selling

In other news, insider Evan Roberts sold 6,268 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $16.36, for a total value of $102,544.48. Following the completion of the sale, the insider directly owned 826,554 shares in the company, valued at $13,522,423.44. The trade was a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Amy Beth Vanduyn sold 2,202 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $16.36, for a total value of $36,024.72. Following the transaction, the senior vice president owned 157,349 shares in the company, valued at $2,574,229.64. This trade represents a 1.38% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 60,766 shares of company stock valued at $1,013,817 in the last 90 days. Corporate insiders own 5.50% of the company’s stock.

Phreesia Stock Performance

Shares of NYSE PHR opened at $12.40 on Wednesday. The company has a market capitalization of $747.60 million, a PE ratio of -123.99 and a beta of 0.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The company’s fifty day moving average price is $14.52 and its 200 day moving average price is $20.07. Phreesia, Inc. has a 1 year low of $11.31 and a 1 year high of $32.76.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Monday, December 8th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.11. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The business had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. During the same quarter in the prior year, the firm posted ($0.25) earnings per share. The company’s revenue was up 12.7% compared to the same quarter last year. On average, research analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.